Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab ... Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old ...

After its approval in 2018, Libtayo made solid annual sales gains from $348 million in 2020 to $578 million two years later. In 2022, Regeneron paid its partner Sanofi $900 million for full rights ...

In a surprise announcement, Regeneron began a dividend at $0.88/share. A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

Currently, the flagship of Regeneron's oncology franchise is Libtayo (cemiplimab-rwlc), which is an anti-PD-1 monoclonal antibody that is approved for the treatment of several types of cancer.

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other checkpoint inhibitors.

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply agreement supports the evaluation of Immuneering’s ...

Its skin cancer drug, Libtayo, brought in sales of $366.9 million, above estimates of $333.5 million. Regeneron bought the global rights to the cancer drug from partner Sanofi in 2022. The company ...

The quarter saw Regeneron grow its revenue by 10% year ... Of its remaining product sales, standouts included cancer drug Libtayo, with a robust 50% gain to $367 million. The company's ...

SNY pays REGN a royalty on such sales. Regeneron records global net product sales of Libtayo and pays Sanofi a royalty on such sales. Total Libtayo sales came in at $366.9 million, up 50% year ...

Down 50% With a 5.9% Dividend Yield, Here's Why This Dirt Cheap Value Stock Is Worth Buying in February Want to Make More Passive Income? These 2 Dividend Stocks Offer Yields Above 6%. Want ...